ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions
View by Date

Tuesday, November 7, 2017

9:00AM-11:00AM
Abstract Number: 2071
A Novel Selective URAT1 Inhibitor, Tei-a, with Potent Uricosuric Property
Metabolic and Crystal Arthropathies Poster II
9:00AM-11:00AM
Abstract Number: 2018
A Novel Ultrasound Scoring System for the Pediatric Knee
Imaging of Rheumatic Diseases Poster II
9:00AM-11:00AM
Abstract Number: 2072
A Pharmacokinetic and Pharmacodynamic Evaluation of URC102, a Potent and Selective Inhibitor of URAT1, after Single and Multiple Oral Administrations in Healthy Volunteers
Metabolic and Crystal Arthropathies Poster II
9:00AM-11:00AM
Abstract Number: 2441
A Phase III, Multicenter, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Similarities between LBEC0101 and Etanercept Reference Product in Terms of Efficacy and Safety in Patients with Active Rheumatoid Arthritis Inadequately Responding to Methotrexate
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars
9:00AM-11:00AM
Abstract Number: 2398
A Population-Based Cohort Study of Chronic Obstructive Pulmonary Disease Among Patients with Rheumatoid Arthritis: Comorbidity and Mortality
Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities
9:00AM-11:00AM
Abstract Number: 2624
A Renal Biopsy Should Not Delay Treatment Initiation in Suspected Lupus Nephritis
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design
9:00AM-11:00AM
Abstract Number: 2742
A Retrospective Study Comparing the Phenotype and Outcomes of Patients with Polyarteritis Nodosa between UK and Turkish Cohorts
Vasculitis Poster III: Other Vasculitis Syndromes
9:00AM-11:00AM
Abstract Number: 2232
A Role for CCR2 in Chronic Behavioral and Neuroimmune Changes in the DMM Model of Osteoarthritis
Pain – Basic and Clinical Aspects Poster
9:00AM-11:00AM
Abstract Number: 2074
A Series of Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Studies to Evaluate the Efficacy, Safety, and Dose-Response Relationship of Orally Administered URC102, a Novel URAT1 Inhibitor, in Korean Patients with Gout
Metabolic and Crystal Arthropathies Poster II
9:00AM-11:00AM
Abstract Number: 2750
A Serum Metabolomic Analysis in Behcet’s  Disease: A Preliminary Study
Vasculitis Poster III: Other Vasculitis Syndromes
9:00AM-11:00AM
Abstract Number: 2058
A Study on Febuxostat Prescribing Practices for Patients with Chronic Gout Previously Managed with Allopurinol at the Veterans Affairs Puget Sound
Metabolic and Crystal Arthropathies Poster II
9:00AM-11:00AM
Abstract Number: 2609
A Systematic Literature Mining and Gene Expression Analysis Identifies Possible Drug Candidates for Repositioning in Lupus
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design
9:00AM-11:00AM
Abstract Number: 2128
A Systematic Review of the Management of Patients with Preexisting Rheumatologic Diseases Receiving Checkpoint Inhibitors for Cancer
Miscellaneous Rheumatic and Inflammatory Diseases Poster II
9:00AM-11:00AM
Abstract Number: 2169
A Two-Center Experience with Rituximab in Patients with Primary Idiopathic Myositis and Overlap Myositis: A Retrospective Observational Study
Muscle Biology, Myositis and Myopathies Poster
9:00AM-11:00AM
Abstract Number: 1932
A2A Adenosine Receptor (A2AR) Stimulation Modulates NR4A2 Orphan Receptor Expression during Osteoclast Differentiation
Biology and Pathology of Bone and Joint Poster II
  • «Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology